NCT07644117Recruiting
Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease
Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease: Pre-Treatment Prediction of Immunogenicity and Response. A Prospective Observational Study.
Source: ClinicalTrials.gov · Last updated 12 Jun 2026
Brief summary (registry, in English)
This observational study aims to identify genes that may affect how patients with inflammatory bowel disease respond to anti-TNF treatment and why some patients lose response to treatment over time. The study will examine whether genetic markers can help predict which patients are more likely to respond to anti-TNF therapy. Participants who have not previously received anti-TNF treatment and are about to start advanced therapy will provide a blood sample to test for the genetic markers. Participants will also undergo regular assessments of current treatment, disease activity, and inflammatory markers during follow-up.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 31 May 2026
- Start date
- 4 Jan 2025
- Primary completion date
- 31 May 2028
- Lead sponsor
- Shmuel Kivity, MD
- Diseases
- Crohn's disease, Ulcerative colitis
- NCT number
- NCT07644117
What you commit to
- Study type: Observational
- Planned participants: 40
- From 4 Jan 2025 to the primary completion date, 31 May 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Unable to provide informed consent
- Anti-TNF experienced
- Unable to complete the study protocol
Who the study is looking for
- Established IBD: Crohn's disease (CD) or ulcerative colitis (UC)
- Anti-TNF naïve
- Clinically active disease (HBI\>5 for CD, p-MS≥ 3 for UC)
- Elevated inflammatory indices CRP\>10 or fecal calprotectin\>250
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dep. of Gastroenterology, Tel Aviv Sourasky Medical Center Coordinator of this site? Confirm its status | Tel Aviv | Israel | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.